Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AMGN
Strong BuyPremium GrowerFLAGAmgen Inc. · Healthcare · United States · $233.8B · Avg Vol: $1.0B/d
Amgen has quality Q69 and momentum M67, but value at V41 is below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
Amgen Inc. is a leading global biotechnology company dedicated to discovering, developing, and manufacturing innovative human therapeutics across oncology, cardiovascular disease, and bone health. The company's competitive moat is built upon its extensive pipeline of biologics, strong intellectual property protection for blockbuster drugs, and significant R&D investment, positioning it as a pioneer in biotechnology leveraging scientific expertise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.3B | 28.2B | 33.4B | 36.8B | 11.8% | 38.1B | 38.9B | 40.2B | 4.6% |
| EPS | 12.18 | 12.56 | 7.62 | 14.33 | 5.6% | 16.12 | 15.12 | 16.01 | 5.7% |
| Shares | 534.0M | 535.4M | 537.0M | 538.8M | +0.9% | 540.6M | — | — | — |
| Debt | 38.9B | 64.6B | 60.1B | 54.6B | 11.9% | 57.3B | — | — | — |
| Equity | 3.7B | 6.2B | 5.9B | 8.7B | 33.2% | — | — | — | — |
| Op CF | 9.7B | 8.5B | 11.5B | 10.0B | 0.8% | 12.5B | — | — | — |
| Inv CF | -6.0B | -26.2B | -1.0B | -1.9B | — | — | — | — | — |
| Fin CF | -4.0B | 21.0B | -9.4B | -10.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMGN | Amgen Inc.(you) | $233.8B | 86 | Strong Buy |
| NVO | Novo Nordisk A/S | $201.6B | 89 | Strong Buy |
| RO.SW | Roche Holding AG | $360.3B | 85 | Strong Buy |
| PFE | Pfizer Inc. | $159.4B | 88 | Strong Buy |
| NOVN.SW | Novartis AG | $290.6B | 81 | Strong Buy |
| ABBV | AbbVie Inc. | $451.5B | 86 | Strong Buy |
| AZN.ST | AstraZeneca PLC | $252.0B | 71 | Buy |
| GILD | Gilead Sciences, Inc. | $180.6B | 74 | Buy |
| GSK.L | GSK plc | $100.5B | 86 | Strong Buy |
| SAN.PA | Sanofi | $107.2B | 93 | Strong Buy |
Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.6%